These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Double-blind crossover comparison of enoximone and placebo in patients with congestive heart failure. Choraria SK; Taylor D; Pilcher J Circulation; 1987 Dec; 76(6):1307-11. PubMed ID: 2960473 [TBL] [Abstract][Full Text] [Related]
4. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group. Narahara KA Am Heart J; 1991 May; 121(5):1471-9. PubMed ID: 1826806 [TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation. Khalife K; Zannad F; Brunotte F; Belhadj K; Juilliere Y; Iannascoli F; Gilgenkrantz JM Am J Cardiol; 1987 Aug; 60(5):75C-79C. PubMed ID: 2956874 [TBL] [Abstract][Full Text] [Related]
6. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure. Weber KT; Janicki JS; Jain MC J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397 [TBL] [Abstract][Full Text] [Related]
7. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. Zipperle G; Butzer F; Dieterich HA; Heinrich F Am J Cardiol; 1987 Aug; 60(5):72C-74C. PubMed ID: 2956873 [TBL] [Abstract][Full Text] [Related]
8. Short-term effects of oral enoximone on hemodynamics, exercise capacity, anaerobic threshold, and arrhythmias in congestive heart failure. Klauss V; Zwehl W; Mudra H; Huber R; Schmidt R; Scheininger M; Vogler A; Tschaidse O; Dieterich HA; Theisen K Klin Wochenschr; 1991 Jul; 69(10):430-5. PubMed ID: 1719270 [TBL] [Abstract][Full Text] [Related]
9. Effects of enoximone on exercise tolerance in patients with mild to moderate heart failure. Itoh H; Taniguchi K; Doi M; Koike A; Sakuma A Am J Cardiol; 1991 Aug; 68(4):360-4. PubMed ID: 1830450 [TBL] [Abstract][Full Text] [Related]
15. Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy. Leier CV; Binkley PF; Starling RC; Huss-Randolph P Am Heart J; 1989 May; 117(5):1092-8. PubMed ID: 2523634 [TBL] [Abstract][Full Text] [Related]
16. A comparison of hemodynamic effects of one-month oral captopril and enoximone treatment for severe congestive heart failure. Scriven AJ; Lipkin DP; Anand IS; Sutton GC; Poole-Wilson PA Am J Cardiol; 1987 Aug; 60(5):68C-71C. PubMed ID: 2956872 [TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854 [TBL] [Abstract][Full Text] [Related]
18. Effects of enoximone on quality of life. Baligadoo SJ; Subratty H; Manraz M; Tarral A; Maiti D; Murday M Int J Cardiol; 1990 Jul; 28 Suppl 1():S29-32. PubMed ID: 2145235 [TBL] [Abstract][Full Text] [Related]
19. Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy. Weber KT; Janicki JS; Jain MC Am J Cardiol; 1986 Sep; 58(7):589-95. PubMed ID: 2944369 [TBL] [Abstract][Full Text] [Related]
20. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Metra M; Eichhorn E; Abraham WT; Linseman J; Böhm M; Corbalan R; DeMets D; De Marco T; Elkayam U; Gerber M; Komajda M; Liu P; Mareev V; Perrone SV; Poole-Wilson P; Roecker E; Stewart J; Swedberg K; Tendera M; Wiens B; Bristow MR; Eur Heart J; 2009 Dec; 30(24):3015-26. PubMed ID: 19700774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]